|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-1-6
|
|
pubmed:abstractText |
In clinical cancer trials for evaluating neoadjuvant chemotherapy, tumor downstaging is frequently used as a surrogate end point for overall survival. We evaluated the surrogacy of tumor downstaging using data from a follow-up observational study in bladder cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
139-43
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16397035-Adult,
pubmed-meshheading:16397035-Aged,
pubmed-meshheading:16397035-Carcinoma, Transitional Cell,
pubmed-meshheading:16397035-Cystectomy,
pubmed-meshheading:16397035-Female,
pubmed-meshheading:16397035-Humans,
pubmed-meshheading:16397035-Male,
pubmed-meshheading:16397035-Middle Aged,
pubmed-meshheading:16397035-Neoadjuvant Therapy,
pubmed-meshheading:16397035-Survival Analysis,
pubmed-meshheading:16397035-Treatment Outcome,
pubmed-meshheading:16397035-Urinary Bladder Neoplasms
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Evaluation for surrogacy of end points by using data from observational studies: tumor downstaging for evaluating neoadjuvant chemotherapy in invasive bladder cancer.
|
|
pubmed:affiliation |
Department of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, Kyoto, Japan. steramu@kuhp.kyoto-u.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
